Related Experiment Video

Updated: Aug 29, 2026

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs
08:58

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs

Published on: October 31, 2025

Hyperinsulinaemic hypoglycaemia in preterm neonates

K Hussain1, A Aynsley-Green

  • 1London Centre for Paediatric Endocrinology and Metabolism, Great Ormond Street Hospital for Children NHS Trust, London WC1N 3JH, UK. K.Hussain@ich.ucl.ac.uk

Archives of Disease in Childhood. Fetal and Neonatal Edition
|January 9, 2004
PubMed

Insights

Severe hyperinsulinism (HI) in premature infants is a serious condition causing recurrent hypoglycemia. This study highlights that HI in preterm infants may present as a more aggressive illness, requiring consideration in differential diagnoses.

Area of Science:

  • Neonatology
  • Pediatric Endocrinology
  • Metabolic Disorders

Background:

  • Hyperinsulinism in infancy (HI) is a primary cause of severe hypoglycemia in newborns.
  • Typically observed in term infants, HI in premature infants is rarely reported.

Purpose of the Study:

  • To report on the occurrence and characteristics of severe persistent hyperinsulinism in a cohort of prematurely born infants.
  • To assess the clinical presentation and management challenges of HI in preterm neonates.

Main Methods:

  • Case series report of seven infants born between 31-36 weeks gestation.
  • Clinical data including gestational age, birth weight, and management difficulties were analyzed.

Main Results:

  • Seven premature infants (31-36 weeks gestation) presented with severe persistent hyperinsulinism.
  • Two infants were large for gestational age; all cases were difficult to manage.
  • This suggests a potentially more aggressive form of HI in the context of prematurity.

Conclusions:

  • Hyperinsulinism in infancy should be considered in the differential diagnosis of severe hypoglycemia in preterm infants.
  • The association of HI with prematurity may indicate a more severe clinical course.
  • Early recognition and management are crucial for affected preterm neonates.

More Related Videos

Transcutaneous Microcirculatory Imaging in Preterm Neonates06:27

Transcutaneous Microcirculatory Imaging in Preterm Neonates

Published on: December 31, 2015

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...